HHS staffers wait for news after government shutdown скачать в хорошем качестве

HHS staffers wait for news after government shutdown

In today’s headlines – 1 October: HHS workers in the US are facing more anxiety after the US government shutdown, following Trump's threat of further mass layoffs. Trump and Pfizer CEO Albert Bourla announced a historic Most Favoured Nation deal, aiming to bring drug prices in line with other countries - and Pfizer is just the first company to sign, the US President promised. Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria. A pioneer of in vivo cell therapy, Umoja, has cleared another regulatory milestone by getting fast-track status for its lead blood cancer programme. Sanofi has confirmed it is being investigated by the European Commission for potentially anticompetitive activity in its vaccines business. Subscribe to @Pharmaphorum for daily news updates and check out www.pharmaphorum.com for more insights and analysis. #news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #novartis #hhs #governmentshutdown #ushealthcare #pfizer #mfn #btkinhibitor #invivo #celltherapy #bloodcancertreatment #fdaapproval #sanofi #europeancommission #vaccines As an official Frontiers Health conference partner, we are pleased to offer pharmaphorum readers an exclusive 20% discount. Don’t miss this unique opportunity to engage with some of the brightest minds in modern healthcare to discuss the biggest trends, opportunities, and challenges facing today’s health innovators. Click below and use promo code: FH25PHP20 to register at a reduced price: https://www.frontiers.health/2025-reg...